Invivyd (IVVD) 2025 Conference Transcript

Invivyd (IVVD) 2025 Conference September 03, 2025 02:10 PM ET Speaker0All right, I think we're ready to get started. Welcome, everyone. I'm Josh Schumer from the Cantor Biotech Equity Research team. Very pleased to introduce from Invivid, Mark Elliott, Chairman of the Board. Mark, give us a very quick snapshot of where Invivid is in prosecuting its portfolio of COVID monoclonal antibodies.Speaker1Sure. Thanks for having us. So, Invivid is a commercial stage company right now. We have an authorized medicine ...